Alzamend Neuro, Inc. ALZN 深 滬
等待開盤 05-19 09:30:00 美东时间
1.035
+0.015
+1.47%
華盛通- 最 高1.05
- 今 開1.05
- 成交量 9793股
- 最 低 1.03
- 昨 收 1.02
- 總市值 393.79万
- 52周最高 8.22
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 0.84
- 委 比 -97.07%
- 總股本 380.47万
- 歷史最高 45292.50
- 量 比 0.48
- 振 幅 1.96%
- 歷史最低 0.84
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a
04-07 20:15
Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium
03-26 20:08
Alzamend Neuro Starts Phase II Clinical Study Of AL001 In Participants With Bipolar Disorder Type 1; Topline Data Anticipated By March End
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major
03-16 20:12
Alzamend Neuro Establishes ATM Equity Offering Agreement
Alzamend Neuro ( ($ALZN) ) has issued an update. On March 6, 2026, Alzamend Neu...
03-07 06:16
Alzamend Neuro Enters ATM Sales Agreement To Sell Up To $3.0M In Common Stock
-SEC Filing
03-07 05:48
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Icecure Medical (NASDAQ:ICCM) shares moved upwards by 17.7% to $0.68 d...
03-02 20:05
Alzamend Neuro Inc. Announces Date for 2026 Annual Meeting of Stockholders
Alzamend Neuro Inc. Announces Date for 2026 Annual Meeting of Stockholders Alzamend Neuro Inc. will hold its 2026 Annual Meeting of Stockholders on April 17, 2026. During the meeting, shareholders will vote on several key proposals, including the election of seven directors, the ratification of the
02-10 05:31
Alzamend Neuro gibt Termin für Hauptversammlung bekannt
Alzamend Neuro gibt Termin für Hauptversammlung bekannt Alzamend Neuro Inc. wird am 17. April 2026 eine Hauptversammlung abhalten. Auf der Tagesordnung steht unter anderem die Wahl der Direktoren. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intel
02-10 05:31
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
